The burden of allergic rhinitis: beyond dollars and cents.
OBJECTIVE
This article presents information about the economic burden of allergic rhinitis and its effect on quality of life. After reading this article, readers should have a greater awareness of the economic impact of this disease and how important it is for both patient and society to diagnose and treat it properly.


METHODS
Relevant and appropriately controlled clinical studies, data compiled from surveys and patient questionnaires, and studies of direct and indirect costs associated with allergic rhinitis were used. Only literature in the English language was reviewed.


METHODS
Material was taken from academic/scholarly journals and appropriate reviews.


RESULTS
Allergic rhinitis occurs in approximately 20% of the general population in the United States. In recent years, its economic impact has increased, with spending for direct and indirect medical costs estimated between 1.5 and $2 billion a year. In addition to its financial burden, however, allergic rhinitis exacts a considerable toll on patients' quality of life, cognitive and learning functions, decision-making, and self-perception. Low energy levels associated with allergic rhinitis can lead to impairments of both memory and decision-making abilities.


CONCLUSIONS
Effective treatment and greater understanding on the part of both physicians and patients can help to reduce direct and indirect costs as well as to lessen the impact of allergic rhinitis on quality of life for both patient and society.
Fineman
Stanley M
SM
Emory University School of Medicine, Atlanta Allergy and Asthma Clinic, Marietta, Georgia 30060-7290, USA. sfineman@atlantaallergy.com
D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D002648:Child; D003071:Cognition; D006801:Humans; D008875:Middle Aged; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000191:economics* / Q000523:psychology; D012649:Self Concept; D017132:Workplace
D018926:Anti-Allergic Agents